- Date2024-09-06
Publication of Review Result of the Second Serious Illness (Cancer) Review Committee of 2023
□ The Health Insurance Review and Assessment Service (President Kang Jung-Gu) releases the results of the deliberations of the 2nd Cancer Review Committee in 2023 on ‘Reimbursement criteria for drugs used for cancer patients’ as follows.
|
Category |
product |
Pharmaceutical company |
Efficacy and effectiveness |
Deliberation results |
|
Application for Healthcare Benefit Reimbursement |
Scemblix Tab (Asciminib) |
Novartis Korea Ltd |
Treatment of adult patients with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) who have been previously treated with 2 or more tyrosine kinase inhibitors (TKIs) |
Reimbursement criteria to be established |
|
Enhertu Inj. (Trastuzumab deruxtecan) |
Daiichi Sankyo Korea Co., Ltd. |
Treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received at least one prior anti-HER2-based therapy |
To be discussed again | |
|
Treatment of patients with locally advanced or metastatic HER-2-positive gastric or gastroesophageal junction adenocarcinoma who have received two or more prior therapies, including anti-HER2 therapy |
To be discussed again | |||
|
Expand reimbursement scope |
Tagrisso Tab (Osimertinib) |
AstraZeneca Korea, Inc |
First-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 (L858R) substitution mutations |
Reimbursement criteria to be established |
|
Darzalex Inj. (Daratumu-mab) |
Janssen Korea, Inc |
Combination therapy with lenalidomide and dexamethasone in patients with multiple myeloma who have received at least one prior therapy |
Reimbursement criteria not to be established | |
|
Combination therapy with bortezomib and dexamethasone in patients with multiple myeloma who have received at least one prior therapy |
Reimbursement criteria not to be established | |||
|
Combination therapy with Carfilzomib and dexamethasone in patients with multiple myeloma who have received at least one prior therapy |
Reimbursement criteria not to be established |
* Pursuant to Article 5 and Article 5.2 of the Rules on the Criteria for National Health Insurance Reimbursement, the President of the Health Insurance Review and Assessment Service may notify the details of the reimbursement criteria and methods for drugs prescribed and administered to seriously ill patients that are designated and notified by the Minister of Health and Welfare after deliberation by the Serious Illness Review Committee. The reimbursement criteria for such drugs may be set differently according to clinical literature, domestic and foreign guidelines, and expert opinions within the scope of efficacy and effectiveness of the Ministry of Food and Drug Safety approval, and the reimbursement decision and criteria may change in the course of subsequent process.
